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Background: The aim of this analysis is to assess the effect of BMI on the one year outcome in patients enrolled into a contemporary PCI trial 
comparing SES with durable polymer to biolimus-eluting stent (BES) with a biodegradable polymer.
Methods: A total of 1707 patients undergoing PCI were randomized to treatment with either BES (n=857) or SES (n=850). Patients were assigned 
to one of three groups according to BMI: normal= <25kg/m2, overweight= 25 to 30 kg/m2, obese= BMI >30 kg/m2. At one year the incidence 
of the composite of cardiac Death, MI, clinically-justified TVR was assessed. In addition clinically-justified TLR and stent thrombosis rates were 
assessed. Cox’s proportional hazard analysis, adjusted for clinical differences, was used to develop models for one year mortality. 
Results: Forty-five percent of the patients (n=770) were overweight, 26% (n=434) were obese and 29% (n=497) had a normal BMI. At one year 
follow-up, the cumulative rate of cardiac death, MI and clinically justified TVR was significantly higher in the obese group (8.7% in normal weight, 
11.3% in overweight and 14.5% in obese patients; p=0.01). BMI (HR= 1.47, 95% CI: 1.02-2.14, p=0.04) was an independent predictor of stent 
thrombosis. Stent type had no impact on the composite of cardiac death, MI, clinically-justified TVR at one year in the three BMI groups (HR: 1.08, 
95% CI: 0.63-1.83, p=0.73).
Conclusions: BMI was an independent predictor of major adverse cardiac events at one year clinical follow-up. The higher incidence of stent 
thrombosis in the obese group may suggest the need for a weight adjusted dose of clopidogrel.
